Limits...
Intravenous Bone Marrow Stem Cell Grafts Preferentially Migrate to Spleen and Abrogate Chronic Inflammation in Stroke.

Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV - Stroke (2015)

Bottom Line: Hematoxylin and eosin staining revealed significant 15% and 30% reductions in striatal infarct and peri-infarct area, and a trend of rescue against neuronal loss in the hippocampus.Human antigen immunostaining revealed 0.03% hBMSCs survived in spleen and only 0.0007% in brain.MSC migration to spleen, but not brain, inversely correlated with reduced infarct, peri-infarct, and inflammation. hBMSC transplantation is therapeutic in chronic stroke possibly by abrogating the inflammation-plagued secondary cell death.

View Article: PubMed Central - PubMed

Affiliation: From the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa.

Show MeSH

Related in: MedlinePlus

Homing and anti-inflammatory effects of bone marrow stromal cells (hBMSCs) survive better in the spleen than the brain. A, Representative merged images showing colocalization of HuNu+ and Hoeschst+ expression from grafted hBMSCs in spleen and brain (ie, striatum) in transplanted stroke rats as opposed to vehicle-infused stroke rats. Top right, Z-stack reconstruction of HuNu+ hBMSCs (green, human-specific antigen) within the spleen colocalized with Hoechst+ (blue, nuclei marker) in hBMSC-transplanted stroke animals. Bottom right, Z-stack reconstruction of HuNu+ hBMSCs (green) within the peri-infarct area of the striatum colocalized with Hoechst+ (blue) in hBMSC-transplanted stroke animals. Quantitative analyses of the estimated number of HuNu+ hBMSCs in the spleen (B) and in the brain (C) of hBMSC-transplanted stroke animals revealed 0.03% of hBMSCs survived in the spleen compared with 0.0007% survival in the brain, indicating that the mean graft survival, and likely preferential migration, of hBMSCs in the spleen was significantly higher than that found in the brain. Scale bar=50 μm. Data are expressed as mean±SEM.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4542567&req=5

Figure 5: Homing and anti-inflammatory effects of bone marrow stromal cells (hBMSCs) survive better in the spleen than the brain. A, Representative merged images showing colocalization of HuNu+ and Hoeschst+ expression from grafted hBMSCs in spleen and brain (ie, striatum) in transplanted stroke rats as opposed to vehicle-infused stroke rats. Top right, Z-stack reconstruction of HuNu+ hBMSCs (green, human-specific antigen) within the spleen colocalized with Hoechst+ (blue, nuclei marker) in hBMSC-transplanted stroke animals. Bottom right, Z-stack reconstruction of HuNu+ hBMSCs (green) within the peri-infarct area of the striatum colocalized with Hoechst+ (blue) in hBMSC-transplanted stroke animals. Quantitative analyses of the estimated number of HuNu+ hBMSCs in the spleen (B) and in the brain (C) of hBMSC-transplanted stroke animals revealed 0.03% of hBMSCs survived in the spleen compared with 0.0007% survival in the brain, indicating that the mean graft survival, and likely preferential migration, of hBMSCs in the spleen was significantly higher than that found in the brain. Scale bar=50 μm. Data are expressed as mean±SEM.

Mentions: Confocal microscopy of hBMSC survival using immunofluorescent demonstrated positive expression in spleen and brain of hBMSC-transplanted stroke animals (Figure 5A). HuNu positive cells were found in the spleen and brain (Figure 5A). The mean graft survival of hBMSCs (ie, HuNu expression) in the spleen was significantly higher than that found in the brain indicating preferential hBMSC migration to the spleen (Student t test, P<0.05). An estimated 0.03% of hBMSCs survived in the spleen compared with 0.0007% survival in the brain (Figure 5B and 5C).


Intravenous Bone Marrow Stem Cell Grafts Preferentially Migrate to Spleen and Abrogate Chronic Inflammation in Stroke.

Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV - Stroke (2015)

Homing and anti-inflammatory effects of bone marrow stromal cells (hBMSCs) survive better in the spleen than the brain. A, Representative merged images showing colocalization of HuNu+ and Hoeschst+ expression from grafted hBMSCs in spleen and brain (ie, striatum) in transplanted stroke rats as opposed to vehicle-infused stroke rats. Top right, Z-stack reconstruction of HuNu+ hBMSCs (green, human-specific antigen) within the spleen colocalized with Hoechst+ (blue, nuclei marker) in hBMSC-transplanted stroke animals. Bottom right, Z-stack reconstruction of HuNu+ hBMSCs (green) within the peri-infarct area of the striatum colocalized with Hoechst+ (blue) in hBMSC-transplanted stroke animals. Quantitative analyses of the estimated number of HuNu+ hBMSCs in the spleen (B) and in the brain (C) of hBMSC-transplanted stroke animals revealed 0.03% of hBMSCs survived in the spleen compared with 0.0007% survival in the brain, indicating that the mean graft survival, and likely preferential migration, of hBMSCs in the spleen was significantly higher than that found in the brain. Scale bar=50 μm. Data are expressed as mean±SEM.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4542567&req=5

Figure 5: Homing and anti-inflammatory effects of bone marrow stromal cells (hBMSCs) survive better in the spleen than the brain. A, Representative merged images showing colocalization of HuNu+ and Hoeschst+ expression from grafted hBMSCs in spleen and brain (ie, striatum) in transplanted stroke rats as opposed to vehicle-infused stroke rats. Top right, Z-stack reconstruction of HuNu+ hBMSCs (green, human-specific antigen) within the spleen colocalized with Hoechst+ (blue, nuclei marker) in hBMSC-transplanted stroke animals. Bottom right, Z-stack reconstruction of HuNu+ hBMSCs (green) within the peri-infarct area of the striatum colocalized with Hoechst+ (blue) in hBMSC-transplanted stroke animals. Quantitative analyses of the estimated number of HuNu+ hBMSCs in the spleen (B) and in the brain (C) of hBMSC-transplanted stroke animals revealed 0.03% of hBMSCs survived in the spleen compared with 0.0007% survival in the brain, indicating that the mean graft survival, and likely preferential migration, of hBMSCs in the spleen was significantly higher than that found in the brain. Scale bar=50 μm. Data are expressed as mean±SEM.
Mentions: Confocal microscopy of hBMSC survival using immunofluorescent demonstrated positive expression in spleen and brain of hBMSC-transplanted stroke animals (Figure 5A). HuNu positive cells were found in the spleen and brain (Figure 5A). The mean graft survival of hBMSCs (ie, HuNu expression) in the spleen was significantly higher than that found in the brain indicating preferential hBMSC migration to the spleen (Student t test, P<0.05). An estimated 0.03% of hBMSCs survived in the spleen compared with 0.0007% survival in the brain (Figure 5B and 5C).

Bottom Line: Hematoxylin and eosin staining revealed significant 15% and 30% reductions in striatal infarct and peri-infarct area, and a trend of rescue against neuronal loss in the hippocampus.Human antigen immunostaining revealed 0.03% hBMSCs survived in spleen and only 0.0007% in brain.MSC migration to spleen, but not brain, inversely correlated with reduced infarct, peri-infarct, and inflammation. hBMSC transplantation is therapeutic in chronic stroke possibly by abrogating the inflammation-plagued secondary cell death.

View Article: PubMed Central - PubMed

Affiliation: From the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa.

Show MeSH
Related in: MedlinePlus